HyperFlex Medical Launches Clinical Evaluation of Innovative Bunion Treatment System

On September 16, 2025, HyperFlex Medical Inc., a pioneering medical technology firm specializing in bunion care, announced a significant advancement in the treatment of bunions. The company has successfully completed the first clinical case evaluation using its HyperFlex® Bunion Correction System. This milestone not only underscores the potential of the technology but also highlights HyperFlex Medical’s commitment to improving patient experiences.

The first case was conducted by Dr. Josef Geldwert at Surgicare of Westside located in New York City. Dr. Geldwert referred to the event as a key milestone that showcases the safety and effectiveness of this innovative technology. The clinical evaluation aims to assess workflow, patient alignment, and recovery outcomes in real-world settings, paving the way for the system’s anticipated commercial release.

In a recent statement, Dr. Geldwert emphasized the revolutionary nature of the HyperFlex system, which allows for bunion correction through a single small incision without cutting bone. This technique is designed to preserve the natural anatomy of the foot, facilitating a swift recovery and promoting immediate weight-bearing. Early results from the initial case are reportedly encouraging, which bodes well for future applications of the system.

Historically, patients suffering from early-stage bunions have been advised to wait for the condition to worsen before considering traditional surgical interventions. These traditional methods often require invasive procedures, such as osteotomies and joint fusions, which involve cutting bone and can result in prolonged recovery times. HyperFlex Medical aims to redefine this narrative with its minimally invasive approach that seeks to correct bunions without compromising the foot’s structural integrity.

Bob Peterhans, CEO of HyperFlex Medical, echoed Dr. Geldwert's sentiments, expressing excitement over the need for a more patient-friendly solution. “HyperFlex offers a less invasive option earlier in the disease process—without compromising alignment or outcomes. We’re excited to see the system in action and grateful to our clinical partners,” he stated.

The HyperFlex system received FDA 510(k) clearance in November 2024 and has obtained issued patents in both the United States and Europe. The company, which is backed by Easton Capital, is now focused on completing its clinical evaluation and preparing for a broader release of the product.

In summary, HyperFlex Medical’s groundbreaking work with its HyperFlex® Bunion Correction System positions the company at the forefront of bunion treatment innovation. As bunions continue to affect millions of individuals globally, the introduction of this less invasive, effective treatment option may significantly improve patient outcomes and enhance the quality of life for those dealing with this common foot condition.

For further information about the HyperFlex Medical innovations and their approach to bunion care, you can visit their website at hyperflexmedical.com.